Sign In
Buy GLUE
$17.59
-0.150 (-0.85%)
At Close: Jun 03, 2026
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 02'nd Jun 2026
BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today an
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 20'th May 2026
BOSTON, May 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today anno
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
12:16pm, Thursday, 07'th May 2026
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.57 per share a year ago.
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
07:00am, Thursday, 07'th May 2026
Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with ele
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 05'th May 2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today anno
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
01:33pm, Tuesday, 21'st Apr 2026
A GLUE executive disposed of 8,000 shares for a transaction value of approximately $141,000 at a weighted average price of around $17.64 per share on April 14, 2026. The sale represented 1.30% of thei
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers CCNE1-directed MGD demonstrated superior selecti
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $32.80 Average PT from Analysts
03:17am, Monday, 30'th Mar 2026
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight research firms that are presently covering the company, Marketbea
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates
09:26am, Tuesday, 17'th Mar 2026
Monte Rosa Therapeutics (GLUE) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to earnings of $0.23 per share a year ago.
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
07:00am, Tuesday, 17'th Mar 2026
Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipat
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment
Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:01am, Thursday, 12'th Mar 2026
Monte Rosa Therapeutics (GLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, i
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Monday, 23'rd Feb 2026
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann
3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher
10:02am, Friday, 06'th Feb 2026
There is a growing sentiment that high-risk stocks—particularly some high-growth tech stocks—will be out of favor in 2026. It's helpful to look at a statement like this on two levels.
